Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma

Key facts

Study ID

NCT01103037

Run by

Novartis Pharmaceuticals

People needed

8

Starts

2010-03-01

Expected to finish

2010-09-01

Last updated by the study team

2020-12-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with moderate persistent asthma

You may not qualify if…

• Smokers
• Any significant disease or illness, other than asthma
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• West Coast Clinical Trials — Cypress, California, United States
• American Health Research — Charlotte, North Carolina, United States
• North Carolina Clinical Research — Raleigh, North Carolina, United States
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Hamburg, Germany
• Novartis Investigative Site — Wiesbaden, Germany
• Novartis Investigative Site — Moscow, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.